Maia Rodolfo C, Silva Leandro L, Mazzeu Eduardo F, Fumian Milla M, de Rezende Claudia M, Doriguetto Antonio C, Corrêa Rodrigo S, Miranda Ana Luisa P, Barreiro Eliezer J, Fraga Carlos Alberto Manssour
Laboratório de Avaliação e Síntese de Substâncias Bioativas, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, PO Box 68023, ZIP 21941902 Rio de Janeiro, RJ, Brazil.
Bioorg Med Chem. 2009 Sep 15;17(18):6517-25. doi: 10.1016/j.bmc.2009.08.009. Epub 2009 Aug 9.
In this work we reported the synthesis and evaluation of the analgesic, anti-inflammatory, and platelet anti-aggregating properties of new 3-(arylideneamino)-2-methyl-6,7-methylenedioxy-quinazolin-4(3H)-one derivatives (3a-j), designed as conformationally constrained analogues of analgesic 1,3-benzodioxolyl-N-acylhydrazones (1) previously developed at LASSBio. Target compounds were synthesized in very good yields exploiting abundant Brazilian natural product safrole (2) as starting material. The pharmacological assays lead us to identify compounds LASSBio-1240 (3b) and LASSBio-1272 (3d) as new analgesic prototypes, presenting an antinociceptive profile more potent and effective than dipyrone and indomethacin used, respectively, as standards in AcOH-induced abdominal constrictions assay and in the formalin test. These results confirmed the success in the exploitation of conformation restriction strategy for identification of novel cyclic N-acylhydrazone analogues with optimized analgesic profile.
在本研究中,我们报道了新型3-(亚芳基氨基)-2-甲基-6,7-亚甲基二氧基喹唑啉-4(3H)-酮衍生物(3a-j)的合成及其镇痛、抗炎和抗血小板聚集特性的评估。这些衍生物被设计为镇痛性1,3-苯并二氧戊环基-N-酰基腙(1)的构象受限类似物,1是之前在LASSBio研发的。以丰富的巴西天然产物黄樟素(2)为起始原料,以非常高的产率合成了目标化合物。药理试验使我们确定化合物LASSBio-1240(3b)和LASSBio-1272(3d)为新的镇痛原型,在乙酸诱导的腹部收缩试验和福尔马林试验中,它们分别作为标准药物,其抗伤害感受作用比安乃近和吲哚美辛更强、更有效。这些结果证实了利用构象限制策略成功鉴定出具有优化镇痛特性的新型环状N-酰基腙类似物。